International AIDS Conference

newsroom

Featured

Conference Coverage
Podcast360
Conference Coverage
09/29/2022
In this podcast, Jennifer Sherwood, PhD, and Elise Lankiewicz, MPH, speak about the current state of trans inclusion in national HIV strategic plans (NSPs) globally, the results from the recent systematic...
09/29/2022
HIV
Davina Canagasabey
HIV
09/23/2022
In this podcast, Davina Canagasabey, with PATH, speaks about delivering responsive, person-centered HIV and primary health care. She also spoke about this topic during her presentation at the International...
09/23/2022
Prevention
Jessica Rodrigues
Prevention
08/30/2022
In this podcast, Jessica Rodrigues, with AVAC: Global Advocacy for HIV Prevention, speaks about ways communities can overcome barriers to the access of pre-exposure prophylaxis (PrEP), including ambitious...
08/30/2022

Clinical Insights

Conference Coverage
Podcast360
Conference Coverage
09/29/2022
In this podcast, Jennifer Sherwood, PhD, and Elise Lankiewicz, MPH, speak about the current state of trans inclusion in national HIV strategic plans (NSPs) globally, the results from the recent systematic...
09/29/2022
HIV
Davina Canagasabey
HIV
09/23/2022
In this podcast, Davina Canagasabey, with PATH, speaks about delivering responsive, person-centered HIV and primary health care. She also spoke about this topic during her presentation at the International...
09/23/2022
Prevention
Jessica Rodrigues
Prevention
08/30/2022
In this podcast, Jessica Rodrigues, with AVAC: Global Advocacy for HIV Prevention, speaks about ways communities can overcome barriers to the access of pre-exposure prophylaxis (PrEP), including ambitious...
08/30/2022
dual prevention pill
Jessica Rodrigues
dual prevention pill
08/24/2022
In this podcast, Jessica Rodrigues, with AVAC: Global Advocacy for HIV Prevention, provides a description of a Dual Prevention Pill and why it can be used as a case study for future multipurpose...
08/24/2022
prevention
Raphael Landovitz, MD
prevention
04/11/2022
In this podcast, Raphael Landovitz, MD, discusses the findings from his recent trial, HPTN 083, which indicates that long-acting cabotegravir injected once every 8 weeks is superior to daily oral TDF/FTC in...
04/11/2022